NCT03210740已完成2 期
A Phase 2, Single-Center, Randomized, Double- Blind, Parallel-Group, Vehicle-Controlled Study Evaluating the Efficacy and Safety of AM001 Cream in the Treatment of Actinic Keratosis (AK) Lesions
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AmDerma
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Complete clearance of all lesions
研究概览
简要总结
To compare the safety and efficacy profiles of AM001 Cream, 7.5% and its vehicle cream in the treatment of Actinic Keratosis (AK) Lesions
详细描述
A Phase 2, Single-Center, Randomized, Double- Blind, Parallel-Group, Vehicle-Controlled Study Evaluating the Efficacy and Safety of AM001 Cream in the Treatment of Actinic Keratosis (AK) Lesions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must provide written informed consent.
- •Subject must be male or non-pregnant females of any race, and any skin type aged 18 to 80 years both inclusive.
- •Subject has 4 to 8 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions, each at least 4 mm in diameter within a 25cm² contiguous treatment area on the face or the balding scalp.
- •Subject is willing to avoid exposure to sunlight, use of tanning booths, sunlamps, or nonprescription UV (ultra-violate) light sources during the study period.ooths, sunlamps, or nonprescription UV (ultra-violate) light sources during the study period.
- •If female subject of childbearing potential, the subject must have a negative urine pregnancy test at Visit 1/ Screening and must have been using an acceptable form of birth control for at least 2 months prior to Visit 1/ Screening and is willing to continue birth control during the study.
- •Subject must be willing and able to understand and comply with the requirements of the study, apply the assigned investigational product as instructed, return for the required study visits, comply with therapy prohibitions.
- •Subject must be in good health, as confirmed by medical history and physical exam, and free from any clinically significant disease/condition, other than actinic keratosis, that might interfere with the study evaluations.
排除标准
- •Subject has very thick and/or hyperkeratotic actinic keratosis AK lesions in the treatment area.
- •Subject has used topical treatment of actinic keratosis in the treatment area with 5-fluorouracil, imiquimod, diclofenac, corticosteroids or retinoids within 1 month prior to Visit 2/Baseline or during the study.
- •Subject has used treatment with PDT (photodynamic therapy) or physical therapies (e. g. cryotherapy, curettage or surgical treatment) in the treatment area within 1 month prior to Visit 2/Baseline or during the study.
- •Subject has used chemical peel, dermabrasion, laser abrasion, PUVA (prosalen plus ultraviolet A) therapy or UVB therapy within 6 months prior to Visit 2/Baseline or during the study.
- •Subject has used immunomodulators or immunosuppressive therapies, interferon, oral corticosteroids, oral retinoids or cytotoxic drugs within 1 month prior to Visit 2/Baseline or during the study.
- •Subject has untreated basal cell carcinoma, squamous cell carcinoma or melanoma in the treatment area.
- •Subject has suntan or tattoos that may interfere with the assessments in the treatment area.
- •Subject has dermatological diseases in the treatment area that may interfere with the assessments, e.g. acute skin inflammation, atopic dermatitis, eczema, rosacea, psoriasis, seborrheic dermatitis, peri-oral dermatitis or hyperpigmentation.
- •Subject who consumes excessive amount of alcohol, abuse or have any condition that in the investigator's opinion would compromise compliance, with this protocol.
- •Subject has history of malignancy not in remission for at least 5 years excluding basal cell carcinoma and nonperiorificial squamous cell carcinoma of the skin.
- •Female subject who is pregnant, nursing or planning a pregnancy within the study participation period
- •Subject has symptoms of a clinically significant illness that may influence the outcome of the study in the 4 weeks prior to Visit 1/Screening.
- •Subject has participated in another clinical trial involving investigational product or device in the 4 weeks prior to Visit 1/Screening.
- •Subject has known allergic reactions to components of the investigational product.
研究组 & 干预措施
AM001 Cream, 7.5%
Experimental
A white to off-white Cream free from any foreign particles
干预措施: AM001 Cream, 7.5% (Drug)
Vehicle Cream
Placebo Comparator
A white to off-white Cream free from any foreign particles
干预措施: Vehicle Cream (Drug)
结局指标
主要结局
Complete clearance of all lesions
时间窗: 8 weeks post treatment
(100 % of all AK lesions cleared) 8 weeks post treatment
次要结局
- Complete clearance of all baseline lesions weeks of treatment(16 weeks)
- Complete clearance of all lesions(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque PsoriasisPlaque PsoriasisNCT03005964AmDerma74
已完成
2 期
Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque PsoriasisSkin Diseases, PapulosquamousSkin DiseasesPlaque PsoriasisNCT01938599AmDerma92
已完成
2 期
Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact DermatitisAllergic Contact DermatitisNCT03680131Edesa Biotech Inc.211
已完成
2 期
Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland DysfunctionPosterior BlepharitisMeibomian Gland DysfunctionNCT04469998AxeroVision, Inc.129
已完成
3 期
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque PsoriasisChronic Stable Plaque PsoriasisNCT02445807Promius Pharma, LLC265